Acceptability of human papillomavirus vaccination and sexual experience prior to disclosure to health care providers among men who have sex with men in Vancouver, Canada: Implications for targeted vaccination programs

Vaccine

Volumn 30, Issue 39, 2012, Pages 5755-5760

  Rank, Claudia ^a,b   Gilbert, Mark ^b,c   Ogilvie, Gina ^b,c   Jayaraman, Gayatri C ^a   Marchand, Rick ^d   Trussler, Terry ^d   Hogg, Robert S ^e,f   Gustafson, Reka ^c,g   Wong, Tom ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Community Based Research Centre ^*  (Canada)

^e BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^f SIMON FRASER UNIVERSITY   (Canada)

^g VANCOUVER COASTAL HEALTH   (Canada)

Author keywords

Canada; Human papillomavirus; Men who have sex with men; Vaccination programs; Vaccine acceptability

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; WART VIRUS VACCINE;

ADULT; ARTICLE; CANADA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DRUG USE; HEALTH CARE PERSONNEL; HUMAN; INCOME; MALE; MALE HOMOSEXUAL; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL BEHAVIOR; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; CANADA; CONDYLOMATA ACUMINATA; DISCLOSURE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOMOSEXUALITY, MALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PHYSICIAN-PATIENT RELATIONS; VACCINATION; YOUNG ADULT;

EID: 84864911225     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.001     Document Type: Article

References (21)

1. Palefsky J.M. HPV infection in men. Dis Markers 2007, 23:261-272.
2. International Agency for Research on Cancer (IARC) IARC monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses 2007, Lyon, France, IARC Press.
3. Piketty C., Selinger-Leneman H., Grabar S., Duvivier C., Bonmarchand M., Abramowitz L., et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008, 22:1203-1211.
4. Frisch M., Biggar R.J., Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000, 92:1500-1510.
5. Johnson L.G., Madeleine M.M., Newcomer L.M., Schwartz S.M., Daling J.R. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004, 101:281-288.
6. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364:401-411.
7. Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D., Aranda C., Jessen H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
8. Kim J.J. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10:845-852.
9. Simatherai D., Bradshaw C.S., Fairley C.K., Bush M., Heley S., Chen M.Y. What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009, 85:148-149.
10. Public Health Agency of Canada. HIV/AIDS: M-Track Survey. Available at: http://www.phac-aspc.gc.ca/aids-sida/about/mtrack-eng.php.
11. Boehner C.W., Howe S.R., Bernstein D.I., Rosenthal S.L. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 2003, 30:774-778.
12. Jones M., Cook R. Intent to receive and HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health 2008, 57:23-32.
13. Lenselink C.H., Schmeink C.E., Melchers W.J., Massuger L.F., Hendriks J.C., van Hamont D., et al. Young adults and acceptance of the human papillomavirus vaccine. Public Health 2008, 122:1295-1301.
14. Gerend M.A., Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009, 36:58-62.
15. Ferris D.G., Waller J.L., Miller J., Patel P., Price G.A., Jackson L., et al. Variables associated with human papillomavirus (HPV) acceptance by men. J Am Board Fam Med 2009, 22:34-42.
16. Reiter P.L., Brewer N.T., McRee A.L., Gilbert P., Smith J.S. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis 2010, 37:197-203.
17. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118:2135-2145.
18. Lu B., Viscidi R.P., Lee J.H., Wu Y., Villa L.L., Lazcano-Ponce E., et al. Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV infection in men study (HIM study). Cancer Epidemiol Biomarkers Prev 2011, 20:990-1002.
19. Gilbert M, Gustafson P, Xia M, Michelow W, Robert W, Trussler T, et al. Impact of statistical adjustment for frequency of venue attendance in the Vancouver site of the M-Track HIV surveillance system. Presented at: 21st Annual Canadian Conference on HIV/AIDS Research. 2012.
20. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29:8443-8450.
21. Media Advisory ACIP recommends all 11-12 year-old males get vaccinated against HPV (Recommendations subject to approval by CDC). Available at: [accessed 18.11.11]. http://www.cdc.gov/media/releases/2011/a1025_ACIP_HPV_Vote.html.